FDA Delays Decision on Lilly's Alzheimer's Drug
TL;DR Summary
Eli Lilly and Company's stock declined after the FDA delayed its decision on donanemab, an anti-amyloid beta antibody for early symptomatic Alzheimer's disease. The FDA will convene an advisory committee to discuss the drug's safety and effectiveness based on data from the TRAILBLAZER-ALZ 2 study. The decision, expected in the first quarter of 2024, has been postponed. Meanwhile, other companies like Biogen and GSK are also making strides in the Alzheimer's treatment space.
- Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab Yahoo Finance
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | Eli Lilly and Company Investors | Eli Lilly and Company
- Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move CNBC
- F.D.A. Delays Action on Closely Watched Alzheimer's Drug The New York Times
- In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drug NBC News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
90%
734 → 73 words
Want the full story? Read the original article
Read on Yahoo Finance